[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-459434-105":59,"doc-detail-459434-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","amyloid-beta-subspecies-in-individuals-with-down-syndrome-biomarkers-poster-presentation-ip-mass-spectrometry-of-plasma","Amyloid-beta subspecies in individuals with Down Syndrome - BIOMARKERS Poster Presentation - IP-Mass Spectrometry of plasma","","Background: Down Syndrome individuals develop Alzheimer’s Disease neuropathology by age 40 due to Chromosome 21 triplication and amyloid precursor protein gene overproduction. Triplication of other Chr21 genes may influence amyloid processing and subspecies production. This study compares plasma Aβ subspecies measured by IP-MS in Down Syndrome, sporadic Alzheimer’s disease, and PS1 mutations. Method: Plasma from cognitively stable adults, DS with prodromal AD, early onset sporadic AD, and PS1 mutation carriers was analyzed for Aβ 1-37, 1-38, 1-40, and 1-42, with additional biomarker assays in DS and event-based modeling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/amyloid-beta-subspecies-in-individuals-with-down-syndrome-biomarkers-poster-presentation-ip-mass-spectrometry-of-plasma/459434/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/amyloid-beta-subspecies-in-individuals-with-down-syndrome-biomarkers-poster-presentation-ip-mass-spectrometry-of-plasma/459434.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main objective?","Question",{"text":112,"@type":113},"To compare plasma amyloid-beta (Aβ) subspecies across Down Syndrome, sporadic Alzheimer’s disease, and PS1 mutations using IP-Mass Spectrometry.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which Aβ subspecies were measured?",{"text":117,"@type":113},"Aβ 1-37, 1-38, 1-40, and 1-42 were measured in the plasma samples.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings in Down Syndrome compared with other groups?",{"text":121,"@type":113},"Down Syndrome individuals showed consistently higher levels of all measured Aβ subspecies versus cognitively stable general population adults, sporadic AD/AD, and PS1 mutation carriers, with specific Aβ ratio differences and distinct age-related patterns in some subspecies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},459434,1790755916,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":129,"read_time":24,"preview_page_count":14,"preview_urls":143},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","DOI: 10. 1002/alz70856_107136  \nBIOMARKERS  \nPOSTER PRESENTATION  \nBIOMARKERS (NON-NEUROIMAGING)  \nAmyloid-beta subspecies in individuals with Down Syndrome, sporadic Alzheimer’s disease (sAD) and PS1 mutationscomparison using IP-Mass Spectrometry of plasma  \nAndre Strydom1, 2, 3  Asaad Baksh4  Marie-Claude Potier5  Laia Mina Idris 1  LedaA Bianchi 1  Nicholas Ashton7  Sarah Pape3, 4 Henrik Zetterberg8, 9  \nMontoliu-Gaya6  \n1 King’s College London, London, United Kingdom  \n2South London and the Maudsley NHS Tust, London, United Kingdom  \n3The LonDownS consortium, London, United Kingdom  \n4 Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom  \n5 ICM Institut du Cerveau et de la Moelle épinière, CNRS UMR7225, INSERM U1127, UPMC, Hôpital de la Pitié-Salpêtrière, 47 Bdde l’Hôpital, F-75013 Paris, France, Paris, France  \n6 Institute of Neuroscienace and Physiology, University of Gothenburg, Mölndal, Västra Götaland, Sweden  \n7 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden  \n8 UCL Institute of Neurology, London, United Kingdom  \n9 Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden  \nCorrespondence  \nAndre Strydom, King’s College London, London, United Kingdom.  \nEmail: [andre.strydom@kcl.ac.uk](andre.strydom@kcl.ac.uk)  \nAbstract  \nBackground: Down Syndrome (DS) individuals develop Alzheimer’s Disease (AD) neuropathology by the age of 40 due to the triplication of Chromosome 21 and the amyloid precursor protein gene. This genetic alteration leads to an overproduction of Aß, resulting in amyloid accumulation. However, triplication of other Chr21 genes may be involved in AD pathogenesis in DS, and affect amyloid processing and alter subspecies production. This study compares plasma Aß subspecies using mass spectrometry (MS) in DS, sAD and PS1 mutations.  \nMethod: Plasma from adultswith DSwho were cognitivelystable(CS-DS; n = 46;mean age 33.5), cognitive stable older adults from the general population (CS; n = 42; mean age71.7), DS deemed prodromalor withAD(DS pAD/AD;n = 25;mean age53.5), early onset sporadic pAD/AD (n = 27; mean age 63. 9) and with presenilin 1 mutations (n = 6; mean age 50.5) were analysed using IP-MS for Aß 1-37, 1-38, 1-40, and 1-42. In those with DS, Simoa assays forAß 40 and 42, neurofilament light (Nfl), glial fibrillary protein (GFAP, pTau181 and pTau231 were also obtained, and an Event-Based Model (EBM) was used to determine the sequence of changes associated with AD.  \nResult: DS individuals had consistently higher levels of Aß1-37, 1-38, 1-40, and 1- 42 compared to CS general population adults, sporadic pAD/AD, and those with PS1 mutations. DS pAD/ AD had increased Aß ratios for 1-40/1-37 and 1-37/ 1- 38 compared to sporadic pAD/AD, but similar ratios when compared to those with PS1 mutations. Age-related patterns of changes in Aβ1-37 and 1-38 subspecies in DS pAD/AD differed compared to sporadic pAD/AD, but changes in Aβ 1-40 and 1- 42 levels were similar. APOE ε4 was associated with Ab 1-37 levels in DS. Changes  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e107136.  \n[https://doi.org/10.1002/alz70856_107136](https://doi.org/10.1002/alz70856_107136)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of2  \nBIOMARKERS  \nAβ1-42/1-38, 1-42/1-37, and 1-42/1-40 were early events followed by changes in NfL, GFAP, pTau 181 and pTau 231.  \nConclusion: All Aß subspecies are increased in DS compared to sAD, with higher 1- 40/1-37 ratios and different age ","cbCaisZRt8Hh4j9X","https://ap.wps.com/l/cbCaisZRt8Hh4j9X","pdf",95768,"English","# BIOMARKERS\n## Poster presentation\n## Background\n## Method\n## Result\n## Conclusion","[{\"question\":\"What was the study’s main objective?\",\"answer\":\"To compare plasma amyloid-beta (Aβ) subspecies across Down Syndrome, sporadic Alzheimer’s disease, and PS1 mutations using IP-Mass Spectrometry.\"},{\"question\":\"Which Aβ subspecies were measured?\",\"answer\":\"Aβ 1-37, 1-38, 1-40, and 1-42 were measured in the plasma samples.\"},{\"question\":\"What were the key findings in Down Syndrome compared with other groups?\",\"answer\":\"Down Syndrome individuals showed consistently higher levels of all measured Aβ subspecies versus cognitively stable general population adults, sporadic AD/AD, and PS1 mutation carriers, with specific Aβ ratio differences and distinct age-related patterns in some subspecies.\"}]","Amyloid-beta subspecies in individuals with Down Syndrome - BIOMARKERS Poster Presentation - IP-Mass Spectrometry of plasma | PDF",[144,148],{"page_no":8,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/b0af363b6c74778ba461994ca6a0910d.webp",983,1291,{"page_no":14,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/ef65efa0c54cbc2ed91c23d09b746d6a.webp",982,1290]